Normal Glucose Regulation and the Pathophysiology of T1DM and T2DM

CDCES Certified Diabetes Care and Education Specialist

Track your progress as you read

Finished sections get a check mark.

1 Introduction & the CDCES Exam

About the CDCES Credential & Current Exam Facts The July 2024 Exam Content Outline & Domain Weights The ADCES7 Self-Care Behaviors Framework

2 Pathophysiology, Classification & Diagnosis

Normal Glucose Regulation and the Pathophysiology of T1DM and T2DM Classification and Diagnostic Criteria Risk Factors and Primary Prevention Treatment Goals and Glycemic Targets

3 Assessment: History, Physical & Data

Health History & Diabetes-Specific Physical Assessment Interpreting Diabetes Measures & Laboratory Data Social Determinants of Health & Psychosocial Wellbeing

4 Assessing Self-Management & Learning

Assessing Self-Management Behaviors & Knowledge Assessing Technology Use, Problem-Solving & Risk-Reduction Behaviors Assessing Learning: Goals, Readiness to Change & Literacy Learning Considerations & Barriers

5 Developing the Education & Care Plan

Developing the Individualized Education/Care Plan Instructional Methods & Person-Centered Teaching Strategies SMART Goals, Behavior-Change Theory & Motivational Interviewing

6 Nutrition Therapy

Nutrition Recommendations & Eating Patterns Carbohydrate Counting & Insulin-Food Timing Fats, Protein, Alcohol & Dietary Supplements Food Labels, Weight Management & Special Nutrition Considerations

7 Physical Activity

Physical Activity Recommendations, Benefits, Challenges & Safety Activity Planning with FITT and Adjusting for Planned & Unplanned Activity

8 Pharmacologic Therapy

Insulin — Types, Pharmacokinetics & Delivery Systems Non-Insulin Glucose-Lowering Agents Guideline-Based Medication Selection Medication Titration & Immunizations for People with Diabetes

9 Monitoring

Glucose Monitoring: SMBG, CGM & Time in Range A1C and Ketone Monitoring Cardiometabolic and Organ System Monitoring

10 Acute Complications

Hypoglycemia Hyperglycemia, DKA, and HHS

11 Chronic Complications

Screening Schedules and Microvascular Disease Macrovascular Disease and Lower-Extremity Foot Care Infections, Dental Disease, Sexual Dysfunction, and Other Comorbidities

12 Special Situations & Populations

Sick-Day Management, Surgery, Travel & Emergency Preparedness Special Populations Across the Lifespan Preconception, Pregnancy, Postpartum & Gestational Diabetes Daily Living, Psychosocial Wellbeing & Safety

13 Evaluation & Documentation

Evaluating Intervention Effectiveness & Outcomes Documentation, Plan Revision & Referral

14 Standards, Guidelines & Professional Practice

National Standards for DSMES and the National DPP Applying Evidence-Based Practice Guidelines Population Health, Health Equity & Advocacy

Normal Glucose Regulation and the Pathophysiology of T1DM and T2DM

Key Takeaways Explain This Topic AI

Insulin, secreted by pancreatic beta cells, lowers blood glucose by promoting cellular glucose uptake and suppressing hepatic glucose production.

Type 1 diabetes results from T-cell-mediated autoimmune destruction of pancreatic beta cells, causing absolute insulin deficiency.

The honeymoon period is a transient partial-remission phase after T1DM diagnosis, not a cure, caused by temporary residual beta-cell function.

Type 2 diabetes involves both insulin resistance and progressive relative insulin deficiency, unlike the absolute deficiency of type 1 diabetes.

The dawn phenomenon is distinguished from the Somogyi effect by checking a 2-3 AM glucose: a normal or rising value suggests dawn phenomenon, while a preceding low suggests Somogyi rebound.

Last updated: July 2026

Normal Glucose Homeostasis

Blood glucose is normally held within a narrow range by the coordinated action of the pancreatic islets of Langerhans. Beta cells secrete insulin in response to rising glucose, largely after meals, while alpha cells secrete glucagon when glucose falls during fasting or exercise. Insulin lowers glucose by promoting glucose uptake into skeletal muscle and adipose tissue (via GLUT4 transporters), stimulating glycogen synthesis in liver and muscle, and suppressing hepatic glucose output (glycogenolysis and gluconeogenesis). Beta cells also co-secrete amylin , which slows gastric emptying and suppresses glucagon after meals, complementing insulin's glucose-lowering action. Glucagon does the opposite: it stimulates hepatic glycogenolysis and gluconeogenesis to release glucose into circulation and protect the brain, which depends on a continuous glucose supply and cannot store its own fuel.

A second layer of control comes from the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), released from the gut after eating. They potentiate glucose-dependent insulin secretion and, in the case of GLP-1, suppress glucagon and slow gastric emptying — the physiologic basis for GLP-1 receptor agonist therapy covered in Chapter 8. When glucose drops too low, counter-regulatory hormones — glucagon, epinephrine, cortisol, and growth hormone — are released in a coordinated cascade to restore normoglycemia and are central to understanding both hypoglycemia recovery and the two overnight glucose patterns discussed below.

Type 1 Diabetes: Autoimmune Beta-Cell Destruction

Type 1 diabetes (T1DM) results from T-cell-mediated autoimmune destruction of pancreatic beta cells , producing an absolute insulin deficiency . It develops in genetically susceptible individuals, strongly linked to HLA-DR3/DR4 genotypes, after an environmental trigger initiates autoimmunity. The process is commonly staged:

Stage 1 — two or more islet autoantibodies present (GAD65, IA-2, insulin autoantibodies/IAA, ZnT8); normal glucose; asymptomatic

• Stage 2 — autoantibodies present with dysglycemia; still asymptomatic
• Stage 3 — symptomatic hyperglycemia meeting diagnostic criteria; clinical onset

Because insulin secretion is essentially absent by clinical onset, people with T1DM require lifelong exogenous insulin from diagnosis; oral agents that rely on residual beta-cell function are not effective monotherapy. Because autoantibody positivity often precedes symptomatic hyperglycemia by months to years, screening at-risk first-degree relatives for islet autoantibodies can identify Stage 1 or Stage 2 disease before diabetic ketoacidosis develops, though this is not yet part of routine primary-care screening for the general population.

The Honeymoon Period (Partial Remission Phase)

Shortly after diagnosis and insulin initiation, many people with new-onset T1DM experience a partial remission, or "honeymoon," period : surviving beta cells recover some function once glucotoxicity is relieved, temporarily lowering insulin requirements — sometimes dramatically. This phase can last weeks to several months. It is not a cure — autoimmune beta-cell destruction continues in the background, and insulin needs reliably climb again as remaining beta-cell mass declines. A core educator responsibility is counseling people and families not to interpret the honeymoon period as remission or to discontinue insulin, and to keep monitoring glucose closely through the transition so basal and bolus doses can be retitrated as needs rise.

Type 2 Diabetes: Insulin Resistance Plus Relative Deficiency

Type 2 diabetes (T2DM) is a progressive disease driven by two intertwined defects: insulin resistance in muscle, liver, and adipose tissue, and relative, not absolute, insulin deficiency from progressive beta-cell dysfunction. Early on, beta cells compensate with hyperinsulinemia; hyperglycemia emerges only once compensation fails. Multiple organ systems contribute beyond the classic muscle-liver-fat triad, including increased glucagon secretion (alpha cells), a blunted incretin effect (gut), increased renal glucose reabsorption (kidney, via SGLT2), and altered appetite regulation (brain) — collectively why modern T2DM therapy targets so many different pathways, as covered in Chapter 8. Insulin resistance itself often precedes a T2DM diagnosis by years and can be suspected clinically through surrogate markers such as central adiposity and acanthosis nigricans, well before glucose values cross the diagnostic thresholds covered in section 2.2. T2DM is strongly associated with obesity, physical inactivity, and genetic predisposition, and unlike T1DM, most people retain some endogenous insulin secretion, at least initially, which is why lifestyle change and non-insulin agents are viable first-line options.

Dawn Phenomenon vs. Somogyi Effect

Both produce unexplained morning hyperglycemia, but by different mechanisms, and distinguishing between them changes the treatment response:

Feature Dawn Phenomenon Somogyi Effect (rebound hyperglycemia)

Mechanism Nocturnal surge in growth hormone, cortisol, and catecholamines increases hepatic glucose output and insulin resistance Theorized: undetected nocturnal hypoglycemia triggers counter-regulatory hormone release, rebounding into hyperglycemia

• Overnight (~2-3 AM) glucose Normal, or already rising Low
• Typical cause Physiologic overnight hormone rhythm Excess evening or bedtime insulin dose

Correct fix Adjust timing or dose of basal insulin to cover the early-morning rise Reduce , not increase, the evening insulin dose

The distinguishing test is a 2-3 AM glucose check , from a fingerstick or a CGM trace: a normal-to-rising overnight value points to dawn phenomenon, while a low overnight value followed by a rebound points to Somogyi effect. CGM data has shown that a true Somogyi-pattern rebound is less common in practice than once believed, but the discrimination remains a core teaching and testing point precisely because the two patterns call for opposite treatment: increasing insulin for what is actually a Somogyi pattern will worsen nocturnal hypoglycemia, while failing to adjust basal insulin for a true dawn phenomenon leaves morning hyperglycemia uncorrected.